4-(4-guanidinobenzoyloxy)phenylacetic acid: RN given refers to monomethanesulfonate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 130394 |
| CHEMBL ID | 433135 |
| SCHEMBL ID | 1649708 |
| SCHEMBL ID | 11417275 |
| MeSH ID | M0131392 |
| Synonym |
|---|
| CHEMBL433135 , |
| 4-(4-guanidinobenzoyloxy)phenylacetic acid |
| benzeneacetic acid, 4-((4-((aminoiminomethyl)amino)benzoyl)oxy)-, monomethanesulfonate |
| foy-251 |
| foy 251 , |
| 71079-09-9 |
| FT-0668867 |
| S3511 |
| 4-[[4-[(aminoiminomethyl)amino]benzoyl]oxy]-benzeneacetic acid monomethanesulfonate |
| SCHEMBL1649708 |
| SCHEMBL11417275 |
| AKOS030614588 |
| DTXSID20991365 |
| {4-[(4-carbamimidamidobenzoyl)oxy]phenyl}acetic acid--methanesulfonic acid (1/1) |
| HY-19727A |
| 4-gbce (methanesulfonate) |
| CS-0016501 |
| 2-[4-[4-(diaminomethylideneamino)benzoyl]oxyphenyl]acetic acid;methanesulfonic acid |
| foy-251 mesylate |
| foy 251camostat metabolite |
| 2-(4-((4-guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt |
| 2-(4-((4-GUANIDINOBENZOYL)OXY)PHENYL)ACETIC ACID--METHANESULFONIC ACID (1/1) |
| EX-A5589 |
| foy251 |
| EN300-7455534 |
| 2-[4-(4-carbamimidamidobenzoyloxy)phenyl]acetic acid; methanesulfonic acid |
| 2-(4-((4-guanidinobenzoyl)oxy)phenyl)acetic acid compound with methanesulfonic acid (1:1) |
| Excerpt | Reference | Relevance |
|---|---|---|
| " For its safe application, the risks of camostat mesylate to induce pharmacokinetic drug-drug interactions with co-administered drugs should be known." | ( Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Bajraktari-Sylejmani, G; Haefeli, WE; Weiss, J, 2021) | 0.62 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prothrombin | Homo sapiens (human) | IC50 (µMol) | 107.5000 | 0.0000 | 0.7107 | 10.0000 | AID211753 |
| Chymotrypsinogen A | Bos taurus (cattle) | IC50 (µMol) | 100.0000 | 0.9800 | 4.0560 | 7.2000 | AID52321 |
| Trypsin-1 | Homo sapiens (human) | IC50 (µMol) | 0.0550 | 0.0035 | 1.5321 | 10.0000 | AID215921 |
| Neutrophil elastase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0063 | 2.0734 | 22.3780 | AID66493 |
| Cathepsin G | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0137 | 2.4224 | 7.4130 | AID48205 |
| Plasminogen | Rattus norvegicus (Norway rat) | IC50 (µMol) | 12.5000 | 0.4300 | 1.5250 | 2.6200 | AID158322 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID158322 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (H-D-Val-Leu-Lys-pNA) for plasmin in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID66493 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (MeO-Suc-Ala-Ala-Pro-Val-pNA) for sputum elastase in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID215921 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (Boc-Phe-Ser-Arg-AMC) for trypsin in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID157534 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (Suc-Ala-Ala-Ala-AMC) for pancreatic elastase in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID95186 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (H-D-Pro-Phe-Arg-pNA) for plasma kallikrein in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID95187 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (H-D-Val-Leu-Arg-pNA) for pancreatic kallikrein in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID211753 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (H-D-Phe-Pip-Arg-pNA) thrombin in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID52321 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (Suc-Ala-Ala-Pro-Phe-pNA) for chymotrypsin in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| AID48205 | Concentration required to inhibit enzymatic cleavage of the chromogenic substrate (MeO-Suc-Ala-Ala-Pro-Met-pNA) for cathepsin G in vitro. | 1995 | Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14 | New orally active serine protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||